Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

Memorial Using Tech to Help Patients Monitor Vitals at Home A 30-second, at-home test can alert those with pre-existing cardiac conditions to abnormalities within their heart before the onset of any ...

Pulmonary hypertension is high blood pressure in your lungs. It has multiple causes, including blood clots, sleep apnea, and left-sided heart disease.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...